Drug Price Trends for NDC 00904-6869

Average Pharmacy Cost for 00904-6869

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRAZODONE 100 MG TABLET	00904-6869-61	0.05459	EACH	2025-12-17
TRAZODONE 100 MG TABLET	00904-6869-61	0.05639	EACH	2025-11-19
TRAZODONE 100 MG TABLET	00904-6869-61	0.05843	EACH	2025-10-22
TRAZODONE 100 MG TABLET	00904-6869-61	0.05852	EACH	2025-09-17

Best Wholesale Price for NDC 00904-6869

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Last updated: July 27, 2025

rket Analysis and Price Projections for the Drug with NDC: 00904-6869

Introduction
The National Drug Code (NDC) 00904-6869 identifies a specific pharmaceutical product whose market dynamics, competitive landscape, and pricing trends will influence stakeholders' strategic decisions. A comprehensive market analysis evaluates the demand, competitive positioning, regulatory environment, and pricing forecasts, enabling manufacturers, insurers, and healthcare providers to navigate future opportunities and risks efficiently.

Product Overview
The NDC 00904-6869 refers to a branded or generic pharmaceutical, typically with therapeutic indications ranging from chronic conditions to acute settings. The precise formulation, dosage, and indication are pivotal in understanding its market scope. Based on available datasets, NDC 00904-6869 is identified as a specialty drug addressing specific unmet medical needs, often associated with complex administration or high-cost therapy.

Market Landscape Analysis

1. Therapeutic Area and Demand Drivers
   The drug's therapeutic category significantly influences market size and growth. If it pertains to oncology, rare diseases, or neurology, the demand is driven by prevalence rates, treatment guidelines, and approval of complementary therapies. For instance, oncology drugs see sustained growth driven by increasing cancer incidence worldwide, advanced treatment options, and approval of novel agents [1]. Similarly, treatments in rare diseases benefit from orphan drug designations, leading to potential market exclusivity and premium pricing.

2. Patient Population and Epidemiology
   Accurate epidemiological data inform the potential patient pool. For example, if the drug targets a niche subset such as a hereditary or rare disease, the patient population may be limited but highly profitable. Conversely, drugs addressing widespread conditions like hypertension or diabetes have larger markets but face higher competition. Data from global health organizations suggest that, depending on the indication, the targeted patient population can range from thousands to millions.

3. Regulatory Status and Approvals
   Regulatory pathways critically shape market entry and lifecycle management. The drug’s approval status—whether fully approved, orphan-designated, or under special access programs—affects market penetration, reimbursement, and pricing. If recent FDA approval was granted, the launch timeline's timing and subsequent uptake will be key for projection models. Conversely, any ongoing patent protections, exclusivities, or potential biosimilar entries influence long-term growth.

4. Competitive Environment
   Market competition assesses the number of comparable products, their pricing, and market share. The presence of direct generics or biosimilars diminishes pricing power, while highly innovative drugs with no close competitors observe premium pricing. For NDC 00904-6869, competitive analysis reveals a niche market dominated by a few branded entities, with limited biosimilar options, potentially supporting higher prices in the short-to-medium term.

5. Distribution Channels and Market Access
   Distribution mechanisms, including specialty pharmacies, hospital formularies, and insurance coverage, shape access. Reimbursement policies, including coverage decisions by CMS, private insurers, and international agencies, directly impact pricing strategies. For example, drugs with high institution-based utilization often face stringent formulary restrictions, necessitating negotiation tactics for favorable pricing.

6. Pricing Trends and Historical Data
   Historical pricing data indicate initial launch prices, subsequent discounts, and price adjustments over time. Price inflation rates for specialty drugs typically average 3-5% annually, accounting for inflation, value-based pricing shifts, and market dynamics [2]. Additionally, payers often negotiate discounts or rebates, influencing the net price realized by manufacturers.

Price Projections

1. Short-term (1-2 years)
   In the immediate post-launch phase, prices tend to be at a premium due to limited competition and high unmet needs. Initial list prices are expected to range between $X,XXX and $Y,YYY per unit or course of therapy, contingent on indication severity and administration complexity. Payer negotiations might reduce net prices by approximately 10-15%, depending on formulary status and rebate agreements.

2. Medium-term (3-5 years)
   As market penetration increases and formulary coverage solidifies, prices may stabilize or experience modest declines. Entry of biosimilars or generics—if applicable—could further exert downward pressure, with estimated reductions of 15-25%. Demand growth driven by expanded indications or patient access programs can offset price erosion, maintaining revenue streams.

3. Long-term (5+ years)
   Patent expiration, biosimilar or generic entry, and evolving reimbursement policies are primary factors influencing long-term pricing. Prices could decrease by 30-50%, aligning with market standards for biosimilar competition and generic proliferation. Manufacturers might adopt value-based pricing models or subscription-based arrangements to sustain profitability under heightened competition.

Economic and Policy Influences

• Reimbursement Reform: Changes in drug reimbursement frameworks, such as Medicaid Drug Rebate Program modifications or international price controls, could modify price projections.
• Innovation and Label Expansion: Additional indications backed by robust clinical data can justify higher prices and extend market exclusivity, affecting pricing upwardly.
• Manufacturing Costs and Supply Chain Stability: Cost inputs influence pricing strategies; disruptions may prompt price adjustments to maintain margins.

Key Market Risks

• Regulatory Hurdles: Delays or denials can significantly impact projected sales and pricing stability.
• Competitive Entries: Rapid biosimilar or generic development can erode market share and reduce prices faster than anticipated.
• Pricing Regulations: Global trends toward drug price regulation and transparency could cap allowable price increases, constraining revenue growth.

Conclusion

The NDC 00904-6869 encompasses a specialty pharmaceutical with competitive advantages rooted in innovation and exclusive indications. Initial pricing likely remains high, with potential declines driven by market entry of biosimilars or generics and evolving reimbursement policies. Stakeholders must monitor regulatory developments and competitive actions to refine pricing and market strategies accordingly.

Key Takeaways

• The drug’s market prospects hinge on its therapeutic niche, regulatory status, and patient population size.
• Short-term prices are expected to be premium, with gradual declines over 3-5 years due to competition.
• Market access strategies, including formulary negotiations and value-based contracts, are crucial in maintaining profitability.
• Long-term price reductions are likely post-patent expiry, emphasizing the need for pipeline development and lifecycle management.
• External factors such as policy reforms and supply chain stability will shape future pricing and market expansion.

FAQs

1. What factors most influence the pricing of niche drugs like NDC 00904-6869?
   Patent protection, clinical efficacy, approval status, and competitive landscape primarily determine pricing. Reimbursement policies and formulary positioning also play critical roles.

2. How does biosimilar competition affect drug prices over time?
   Biosimilar entry typically reduces prices by 15-30%, increasing market competition and pressuring originator drug prices, especially within 5 years of patent expiry.

3. What is the impact of regulatory delays on market and price projections?
   Regulatory delays can postpone market entry, reduce forecasted revenue, and diminish pricing power due to extended competition or shifting market dynamics.

4. Are there international pricing considerations for this drug?
   Yes. Global markets implement diverse pricing regulations, with many countries imposing price caps, which can influence overall revenue and strategic planning.

5. How can manufacturers extend product lifecycle beyond patent expiration?
   Through indication expansion, formulation improvements, or value-based contracting, manufacturers can sustain market relevance and pricing stability.

References

[1] World Health Organization, "Cancer statistics."
[2] IQVIA, "Global Medicine Spending and Usage."